Vascular Smooth Muscle

Vascular Medicine: A Companion to Braunwald's Heart Disease: Second Edition

Volumn , Issue , 2013, Pages 25-42

  Hilenski, Lula L ^a   Griendling, Kathy K ^b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84943257789     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2930-6.00003-3     Document Type: Chapter

References (170)

1. Wagenseil J.E., Mecham R.P. Vascular extracellular matrix and arterial mechanics. Physiol Rev 2009, 89(3):957-989.
2. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004, 84(3):767-801.
3. Beamish J.A., He P., Kottke-Marchant K., et al. Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering. Tissue Eng Part B Rev 2010, 16(5):467-491.
4. Herbert S.P., Huisken J., Kim T.N., et al. Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science 2009, 326(5950):294-298.
5. Swift M.R., Weinstein B.M. Arterial-venous specification during development. Circ Res 2009, 104(5):576-588.
6. Anderson L.M., Gibbons G.H. Notch: a mastermind of vascular morphogenesis. J Clin Invest 2007, 117(2):299-302.
7. Jain R.K. Molecular regulation of vessel maturation. Nat Med 2003, 9(6):685-693.
8. Majesky M.W. Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb Vasc Biol 2007, 27(6):1248-1258.
9. Hao H., Gabbiani G., Bochaton-Piallat M.-L. Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol 2003, 23(9):1510-1520.
10. Larsson E., McLean S.E., Mecham R.P., et al. Do two mutually exclusive gene modules define the phenotypic diversity of mammalian smooth muscle?. Mol Genet Genomics 2008, 280(2):127-137.
11. Moiseeva E.P. Adhesion receptors of vascular smooth muscle cells and their functions. Cardiovasc Res 2001, 52(3):372-386.
12. Rensen S.S., Doevendans P.A., van Eys G.J. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J 2007, 15(3):100-108.
13. Rzucidlo E.M. Signaling pathways regulating vascular smooth muscle cell differentiation. Vascular 2009, 17(Suppl 1):S15-S20.
14. Orr A.W., Hastings N.E., Blackman B.R., et al. Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J Vasc Res 2010, 47(2):168-180.
15. Berk B.C. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev 2001, 81(3):999-1030.
16. Griendling K., Harrison D., Alexander R. Biology of the vessel wall. Hurst's the heart 2008, 135-154. McGraw Hill, New York. ed 12,. V. Fuster, R. Walsh, R. O'Rourke, P. Poole-Wilson (Eds.).
17. Garrido A.M., Griendling K.K. NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol 2009, 302(2):148-158.
18. Pardali E., Goumans M.-J., ten Dijke P. Signaling by members of the TGF-β family in vascular morphogenesis and disease. Trends Cell Biol 2010, 20(9):556-567.
19. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007, 292(1):C82-C97.
20. Yoshida T., Owens G.K. Molecular determinants of vascular smooth muscle cell diversity. Circ Res 2005, 96(3):280-291.
21. High F.A., Zhang M., Proweller A., et al. An essential role for Notch in neural crest during cardiovascular development and smooth muscle differentiation. J Clin Invest 2007, 117(2):353-363.
22. Gridley T. Notch signaling in the vasculature. Curr Top Dev Biol 2010, 92:277-309.
23. Tang Y., Urs S., Liaw L. Hairy-related transcription factors inhibit Notch-induced smooth muscle α-actin expression by interfering with Notch intracellular domain/CBF-1 complex interaction with the CBF-1-binding site. Circ Res 2008, 102(6):661-668.
24. Tang Y., Urs S., Boucher J., et al. Notch and transforming growth factor-beta (TGFβ) signaling pathways cooperatively regulate vascular smooth muscle cell differentiation. J Biol Chem 2010, 285(23):17556-17563.
25. Morrow D., Cullen J.P., Liu W., et al. Sonic hedgehog induces Notch target gene expression in vascular smooth muscle cells via VEGF-A. Arterioscler Thromb Vasc Biol 2009, 29(7):1112-1118.
26. Jin S., Hansson E.M., Tikka S., et al. Notch signaling regulates platelet-derived growth factor receptor-β expression in vascular smooth muscle cells. Circ Res 2008, 102(12):1483-1491.
27. Wang D.-Z., Olson E.N. Control of smooth muscle development by the myocardin family of transcriptional coactivators. Curr Opin Genet Dev 2004, 14(5):558-566.
28. Miano J.M., Long X., Fujiwara K. Serum response factor: master regulator of the actin cytoskeleton and contractile apparatus. Am J Physiol Cell Physiol 2007, 292(1):C70-C81.
29. Parmacek M.S. Myocardin-related transcription factors: critical coactivators regulating cardiovascular development and adaptation. Circ Res 2007, 100(5):633-644.
30. Pipes G.C., Creemers E.E., Olson E.N. The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev 2006, 20(12):1545-1556.
31. Davis C.A., Haberland M., Arnold M.A., et al. PRISM/PRDM6, a transcriptional repressor that promotes the proliferative gene program in smooth muscle cells. Mol Cell Biol 2006, 26(7):2626-2636.
32. Haldar S.M., Ibrahim O.A., Jain M.K. Kruppel-like factors (KLFs) in muscle biology. J Mol Cell Cardiol 2007, 43(1):1-10.
33. Zheng B., Han M., Wen J.K. Role of Krüppel-like factor 4 in phenotypic switching and proliferation of vascular smooth muscle cells. IUBMB Life 2010, 62(2):132-139.
34. Miano J.M. Deck of CArGs. Circ Res 2008, 103(1):13-15.
35. Olson E.N., Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol 2010, 11(5):353-365.
36. Liu N., Olson E.N. Coactivator control of cardiovascular growth and remodeling. Curr Opin Cell Biol 2006, 18(6):715-722.
37. Posern G., Treisman R. Actin' together: serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol 2006, 16(11):588-596.
38. Parmacek M.S. Myocardin: dominant driver of the smooth muscle cell contractile phenotype. Arterioscler Thromb Vasc Biol 2008, 28(8):1416-1417.
39. Dong J.-T., Chen C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell Mol Life Sci 2009, 66(16):2691-2706.
40. Kawai-Kowase K., Owens G.K. Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells. Am J Physiol Cell Physiol 2007, 292(1):C59-C69.
41. Liu Y. Wen J-K, Dong L-H, et al: Kruppel-like factor (KLF) 5 mediates cyclin D1 expression and cell proliferation via interaction with c-Jun in Ang II-induced VSMCs. Acta Pharmacol Sin 2009, 31(1):10-18.
42. Suzuki T., Sawaki D., Aizawa K., et al. Kruppel-like factor 5 shows proliferation-specific roles in vascular remodeling, direct stimulation of cell growth, and inhibition of apoptosis. J Biol Chem 2009, 284(14):9549-9557.
43. Nagai R., Suzuki T., Aizawa K., et al. Significance of the transcription factor KLF5 in cardiovascular remodeling. J Thromb Haemost 2005, 3(8):1569-1576.
44. Liu N., Olson E.N. MicroRNA regulatory networks in cardiovascular development. Dev Cell 2010, 18(4):510-525.
45. Eulalio A., Huntzinger E., Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell 2008, 132(1):9-14.
46. Djuranovic S., Nahvi A., Green R. A parsimonious model for gene regulation by miRNAs. Science 2011, 331(6017):550-553.
47. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136(2):215-233.
48. Cheng Y., Liu X., Yang J., et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009, 105(2):158-166.
49. Cordes K.R., Sheehy N.T., White M.P., et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009, 460(7256):705-710.
50. Xin M., Small E.M., Sutherland L.B., et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009, 23(18):2166-2178.
51. Boettger T., Beetz N., Kostin S., et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009, 119(9):2634-2647.
52. Song Z., Li G. Role of specific microRNAs in regulation of vascular smooth muscle cell differentiation and the response to injury. J Cardiovasc Transl Res 2010, 3(3):246-250.
53. Liu X., Cheng Y., Zhang S., et al. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 2009, 104(4):476-487.
54. Davis B.N., Hilyard A.C., Nguyen P.H., et al. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J Biol Chem 2009, 284(6):3728-3738.
55. McDonald O.G., Owens G.K. Programming smooth muscle plasticity with chromatin dynamics. Circ Res 2007, 100(10):1428-1441.
56. McDonald O.G., Wamhoff B.R., Hoofnagle M.H., et al. Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo. J Clin Invest 2006, 116(1):36-48.
57. Mohammad H.P., Baylin S.B. Linking cell signaling and the epigenetic machinery. Nat Biotech 2010, 28(10):1033-1038.
58. 1 signaling. Biochem Biophys Res Commun 2006, 348(2):351-358.
59. Villeneuve L.M., Reddy M.A., Lanting L.L., et al. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci U S A 2008, 105(26):9047-9052.
60. Ceriello A., Ihnat M.A., Thorpe J.E. The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?. J Clin Endocrinol Metab 2009, 94(2):410-415.
61. Paik J.H., Skoura A., Chae S.S., et al. Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. Genes Dev 2004, 18(19):2392-2403.
62. George S.J., Dwivedi A. MMPs, cadherins, and cell proliferation. Trends Cardiovasc Med 2004, 14(3):100-105.
63. Figueroa X.F., Duling B.R. Gap junctions in the control of vascular function. Antioxid Redox Signal 2009, 11(2):251-266.
64. Brisset A.C., Isakson B.E., Kwak B.R. Connexins in vascular physiology and pathology. Antioxid Redox Signal 2009, 11(2):267-282.
65. Johnstone S., Isakson B., Locke D. Biological and biophysical properties of vascular connexin channels. Int Rev Cell Mol Biol 2009, 278:69-118.
66. Wang L., Zheng J., Du Y., et al. Cartilage oligomeric matrix protein maintains the contractile phenotype of vascular smooth muscle cells by interacting with α7β1 integrin. Circ Res 2010, 106(3):514-525.
67. Tkachenko E., Rhodes J.M., Simons M. Syndecans: new kids on the signaling block. Circ Res 2005, 96(5):488-500.
68. Alexopoulou A.N., Multhaupt H.A.B., Couchman J.R. Syndecans in wound healing, inflammation and vascular biology. Int J Biochem Cell Biol 2007, 39(3):505-528.
69. Fukai N., Kenagy R.D., Chen L., et al. Syndecan-1: an inhibitor of arterial smooth muscle cell growth and intimal hyperplasia. Arterioscler Thromb Vasc Biol 2009, 29(9):1356-1362.
70. Kelleher C.M., McLean S.E., Mecham R.P. Vascular extracellular matrix and aortic development. Curr Top Dev Biol 2004, 62:153-188.
71. Hynes R.O. The extracellular matrix: not just pretty fibrils. Science 2009, 326(5957):1216-1219.
72. Järveläinen H., Sainio A., Koulu M., et al. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009, 61(2):198-223.
73. Mao Y., Schwarzbauer J.E. Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol 2005, 24(6):389-399.
74. Singh P., Carraher C., Schwarzbauer J.E. Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol 2010, 26:397-419.
75. Orr A.W., Lee M.Y., Lemmon J.A., et al. Molecular mechanisms of collagen isotype-specific modulation of smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 2009, 29(2):225-231.
76. Koyama H., Raines E.W., Bornfeldt K.E., et al. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 1996, 87(6):1069-1078.
77. Kielty C.M., Sherratt M.J., Shuttleworth C.A. Elastic fibres. J Cell Sci 2002, 115(14):2817-2828.
78. Kielty C.M. Elastic fibres in health and disease. Expert Rev Mol Med 2006, 8(19):1-23.
79. Karnik S.K., Brooke B.S., Bayes-Genis A., et al. A critical role for elastin signaling in vascular morphogenesis and disease. Development 2003, 130(2):411-423.
80. Ramirez F., Rifkin D.B. Extracellular microfibrils: contextual platforms for TGFβ and BMP signaling. Curr Opin Cell Biol 2009, 21(5):616-622.
81. Ramirez F., Sakai L. Biogenesis and function of fibrillin assemblies. Cell Tissue Res 2010, 339(1):71-82.
82. Yanagisawa H., Davis E.C. Unraveling the mechanism of elastic fiber assembly: the roles of short fibulins. Int J Biochem Cell Biol 2010, 42(7):1084-1093.
83. Chapman S.L., Sicot F.-X., Davis E.C., et al. Fibulin-2 and fibulin-5 cooperatively function to form the internal elastic lamina and protect from vascular injury. Arterioscler Thromb Vasc Biol 2010, 30(1):68-74.
84. Zacchigna L., Vecchione C., Notte A., et al. Emilin1 links TGF-β maturation to blood pressure homeostasis. Cell 2006, 124(5):929-942.
85. Zanetti M., Braghetta P., Sabatelli P., et al. EMILIN-1 deficiency induces elastogenesis and vascular cell defects. Mol Cell Biol 2004, 24(2):638-650.
86. Couchman J.R. Transmembrane signaling proteoglycans. Annu Rev Cell Dev Biol 2010, 26:89-114.
87. Wight T.N. Arterial remodeling in vascular disease: a key role for hyaluronan and versican. Front Biosci 2008, 13:4933-4937.
88. Ballinger M.L., Ivey M.E., Osman N., et al. Endothelin-1 activates ETA receptors on human vascular smooth muscle cells to yield proteoglycans with increased binding to LDL. Atherosclerosis 2009, 205(2):451-457.
89. Chen C.-C., Lau L.F. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 2009, 41(4):771-783.
90. Matsumae H., Yoshida Y., Ono K., et al. CCN1 knockdown suppresses neointimal hyperplasia in a rat artery balloon injury model. Arterioscler Thromb Vasc Biol 2008, 28(6):1077-1083.
91. Shimoyama T., Hiraoka S., Takemoto M., et al. CCN3 inhibits neointimal hyperplasia through modulation of smooth muscle cell growth and migration. Arterioscler Thromb Vasc Biol 2010, 30(4):675-682.
92. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005, 85(1):1-31.
93. Newby A.C. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006, 69(3):614-624.
94. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69(3):562-573.
95. Raffetto J.D., Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008, 75(2):346-359.
96. Newby A.C. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007, 17(8):253-258.
97. Assoian R.K., Klein E.A. Growth control by intracellular tension and extracellular stiffness. Trends Cell Biol 2008, 18(7):347-352.
98. Klein E.A., Yin L., Kothapalli D., et al. Cell-cycle control by physiological matrix elasticity and in vivo tissue stiffening. Curr Biol 2009, 19(18):1511-1518.
99. Watanabe H., Murakami M., Ohba T., et al. TRP channel and cardiovascular disease. Pharmacol Ther 2008, 118(3):337-351.
100. 2+-dependent regulation of vascular tone. J Anesth 2007, 21(2):220-231.
101. Kim H.R., Appel S., Vetterkind S., et al. Smooth muscle signalling pathways in health and disease. J Cell Mol Med 2008, 12(6A):2165-2180.
102. Essin K., Gollasch M. Role of ryanodine receptor subtypes in initiation and formation of calcium sparks in arterial smooth muscle: comparison with striated muscle 2009, J Biomed Biotechnol.
103. 2+ reuptake in human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2009, 297(1):L26-L34.
104. Trebak M., Ginnan R., Singer H.A., et al. Interplay between calcium and reactive oxygen/nitrogen species: an essential paradigm for vascular smooth muscle signaling. Antioxid Redox Signal 2010, 12(5):657-674.
105. Berk B. Vascular smooth muscle. Vascular medicine: a companion to Braunwald's heart disease 2006, 17-30. Saunders-Elsevier, Philadelphia. ed 1,. M. Creager, V. Dzau, J. Loscalzo (Eds.).
106. Hilgers R.H.P., Webb R.C. Molecular aspects of arterial smooth muscle contraction: focus on Rho. Exp Biol Med 2005, 230(11):829-835.
107. Masaki T. Historical review: endothelin. Trends Pharmacol Sci 2004, 25(4):219-224.
108. Tsutsui M., Shimokawa H., Otsuji Y., et al. Pathophysiological relevance of NO signaling in the cardiovascular system: novel insight from mice lacking all NO synthases. Pharmacol Ther 2010, 128(3):499-508.
109. Gao Y., Yang Y., Guan Q., et al. IL-1beta modulate the Ca(2+)-activated big-conductance K channels (BK) via reactive oxygen species in cultured rat aorta smooth muscle cells. Mol Cell Biochem 2010, 338(1-2):59-68.
110. Tong X., Hou X., Jourd'heuil D., et al. Upregulation of Nox4 by TGFβ1 oxidizes SERCA and inhibits NO in arterial smooth muscle of the prediabetic Zucker rat. Circ Res 2010, 107(8):975-983.
111. Rajsheker S., Manka D., Blomkalns A.L., et al. Crosstalk between perivascular adipose tissue and blood vessels. Curr Opin Pharmacol 2010, 10(2):191-196.
112. Zhang H., Cui J., Zhang C. Emerging role of adipokines as mediators in atherosclerosis. World J Cardiol 2010, 2(11):370-376.
113. Fuster J.J., Fernandez P., Gonzalez-Navarro H., et al. Control of cell proliferation in atherosclerosis: insights from animal models and human studies. Cardiovasc Res 2010, 86(2):254-264.
114. Griendling K.K., Ushio-Fukai M., Lassegue B., et al. Angiotensin II signaling in vascular smooth muscle: new concepts. Hypertension 1997, 29(1):366-370.
115. Schwartz M.A., Assoian R.K. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J Cell Sci 2001, 114(14):2553-2560.
116. Dzau V.J., Braun-Dullaeus R.C., Sedding D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 2002, 8(11):1249-1256.
117. Marsboom G., Archer S.L. Pathways of proliferation: new targets to inhibit the growth of vascular smooth muscle cells. Circ Res 2008, 103(10):1047-1049.
118. Fuster J.J., Andres V. Telomere biology and cardiovascular disease. Circ Res 2006, 99(11):1167-1180.
119. Kandadi M.R., Stratton M.S., Ren J. The role of Src homology 2 containing protein tyrosine phosphatase 2 in vascular smooth muscle cell migration and proliferation. Acta Pharmacol Sin 2010, 31(10):1277-1283.
120. Abizaid A. Sirolimus-eluting coronary stents: a review. Vasc Health Risk Manag 2007, 3(2):191-201.
121. Kahl C.R., Means A.R. Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocr Rev 2003, 24(6):719-736.
122. 2+, calmodulin, and cyclins in vascular smooth muscle cell cycle. Circ Res 2006, 98(10):1240-1243.
123. Choi J., Husain M. Calmodulin-mediated cell cycle regulation: new mechanisms for old observations. Cell Cycle 2006, 5(19):2183-2186.
124. Touyz R.M., Yao G. Modulation of vascular smooth muscle cell growth by magnesium-role of mitogen-activated protein kinases. J Cell Physiol 2003, 197(3):326-335.
125. Burg E.D., Remillard C.V., Yuan J.X.J. Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic implications. Br J Pharmacol 2008, 153(S1):S99-S111.
126. Neylon C.B. Potassium channels and vascular proliferation. Vasc Pharmacol 2002, 38(1):35-41.
127. Cidad P., Moreno-Dominguez A., Novensa L., et al. Characterization of ion channels involved in the proliferative response of femoral artery smooth muscle cells. Arterioscler Thromb Vasc Biol 2010, 30(6):1203-1211.
128. Miguel-Velado E., Perez-Carretero F.D., Colinas O., et al. Cell cycle-dependent expression of Kv3.4 channels modulates proliferation of human uterine artery smooth muscle cells. Cardiovasc Res 2010, 86(3):383-391.
129. Jackson W.F. KV1.3: a new therapeutic target to control vascular smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol 2010, 30(6):1073-1074.
130. Assoian R.K., Schwartz M.A. Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet Dev 2001, 11(1):48-53.
131. Gizard F., Bruemmer D. Transcriptional control of vascular smooth muscle cell proliferation by peroxisome proliferator-activated receptor-gamma: therapeutic implications for cardiovascular diseases 2008, PPAR Res.
132. Gizard F., Amant C., Barbier O., et al. PPARα inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest 2005, 115(11):3228-3238.
133. Gizard F., Nomiyama T., Zhao Y., et al. The PPARα/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation. Circ Res 2008, 103(10):1155-1163.
134. Koyama H., Bornfeldt K.E., Fukumoto S., et al. Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol 2001, 186(1):1-10.
135. Wu Y.-J., Sala-Newby G.B., Shu K.-T., et al. S-phase kinase-associated protein-2 (Skp2) promotes vascular smooth muscle cell proliferation and neointima formation in vivo. J Vasc Surg 2009, 50(5):1135-1142.
136. Cheng Y., Zhang C. MicroRNA-21 in cardiovascular disease. J Cardiovasc Trans l Res 2010, 3(3):251-255.
137. Gerthoffer W.T. Mechanisms of vascular smooth muscle cell migration. Circ Res 2007, 100(5):607-621.
138. San Martín A., Griendling K.K. Redox control of vascular smooth muscle migration. Antioxid Redox Signal 2010, 12(5):625-640.
139. Seasholtz T.M., Majumdar M., Kaplan D.D., et al. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 1999, 84(10):1186-1193.
140. Landry D.B., Couper L.L., Bryant S.R., et al. Activation of the NF-kappa B and I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol 1997, 151(4):1085-1095.
141. Sun L., Stoecklin G., Van Way S., et al. Tristetraprolin (TTP)-14-3-3 complex formation protects TTP from dephosphorylation by protein phosphatase 2a and stabilizes tumor necrosis factor-alpha mRNA. J Biol Chem 2007, 282(6):3766-3777.
142. Pyronnet S. Phosphorylation of the cap-binding protein eIF4E by the MAPK-activated protein kinase Mnk1. Biochem Pharmacol 2000, 60(8):1237-1243.
143. Yin B.L., Hao H., Wang Y.Y., et al. Downregulating osteopontin reduces angiotensin II-induced inflammatory activation in vascular smooth muscle cells. Inflamm Res 2009, 58(2):67-73.
144. Cuff C.A., Kothapalli D., Azonobi I., et al. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest 2001, 108(7):1031-1040.
145. Vicencio J.M., Galluzzi L., Tajeddine N., et al. Senescence, apoptosis or autophagy? When a damaged cell must decide its path-a mini-review. Gerontology 2008, 54(2):92-99.
146. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007, 8(9):729-740.
147. Gorenne I., Kavurma M., Scott S., et al. Vascular smooth muscle cell senescence in atherosclerosis. Cardiovasc Res 2006, 72(1):9-17.
148. Minamino T., Miyauchi H., Yoshida T., et al. Vascular cell senescence and vascular aging. J Mol Cell Cardiol 2004, 36(2):175-183.
149. Burton D.G., Matsubara H., Ikeda K. Pathophysiology of vascular calcification: pivotal role of cellular senescence in vascular smooth muscle cells. Exp Gerontol 2010, 45(11):819-824.
150. Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008, 9(3):231-241.
151. Muto A., Fitzgerald T.N., Pimiento J.M., et al. Smooth muscle cell signal transduction: implications of vascular biology for vascular surgeons. J Vasc Surg 2007, 45(6 Suppl 1):A15-A24.
152. Geng Y.-J., Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol 2002, 22(9):1370-1380.
153. Gupta S., Kass G.E., Szegezdi E., et al. The mitochondrial death pathway: a promising therapeutic target in diseases. J Cell Mol Med 2009, 13(6):1004-1033.
154. Clarke M.C.H., Talib S., Figg N.L., et al. Vascular smooth muscle cell apoptosis induces interleukin-1-directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ Res 2010, 106(2):363-372.
155. Clarke M., Bennett M. Defining the role of vascular smooth muscle cell apoptosis in atherosclerosis. Cell Cycle 2006, 5(20):2329-2331.
156. Son B.K., Akishita M., Iijima K., et al. Mechanism of pi-induced vascular calcification. J Atheroscler Thromb 2008, 15(2):63-68.
157. Martinet W., De Meyer G.R. Autophagy in atherosclerosis. Curr Atheroscler Rep 2008, 10(3):216-223.
158. Hirschi K.K., Majesky M.W. Smooth muscle stem cells. Anat Rec Part A: Disc Mol Cell Evo Biol 2004, 276A(1):22-33.
159. Margariti A., Zeng L., Xu Q. Stem cells, vascular smooth muscle cells and atherosclerosis. Histol Histopathol 2006, 21(9):979-985.
160. Orlandi A., Bennett M. Progenitor cell-derived smooth muscle cells in vascular disease. Biochem Pharmacol 2010, 79(12):1706-1713.
161. Ergün S., Tilki D., Klein D. Vascular wall as a reservoir for different types of stem and progenitor cells. Antioxid Redox Signal 2011, Jan 7.
162. Sinha S., Wamhoff B.R., Hoofnagle M.H., et al. Assessment of contractility of purified smooth muscle cells derived from embryonic stem cells. Stem Cells 2006, 24(7):1678-1688.
163. Nandan M.O., Yang V.W. The role of Kruppel-like factors in the reprogramming of somatic cells to induced pluripotent stem cells. Histol Histopathol 2009, 24(10):1343-1355.
164. Wang C., Yin S., Cen L., et al. Differentiation of adipose-derived stem cells into contractile smooth muscle cells induced by transforming growth factor-beta1 and bone morphogenetic protein-4. Tissue Eng Part A 2010, 16(4):1201-1213.
165. Daniel J.-M., Bielenberg W., Stieger P., et al. Time-course analysis on the differentiation of bone marrow-derived progenitor cells into smooth muscle cells during neointima formation. Arterioscler Thromb Vasc Biol 2010, 30(10):1890-1896.
166. Hoglund V.J., Dong X.R., Majesky M.W. Neointima formation: a local affair. Arterioscler Thromb Vasc Biol 2010, 30(10):1877-1879.
167. Passman J.N., Dong X.R., Wu S.P., et al. A sonic hedgehog signaling domain in the arterial adventitia supports resident Sca1+ smooth muscle progenitor cells. Proc Natl Acad Sci U S A 2008, 105(27):9349-9354.
168. Dotsenko O. Stem/Progenitor cells, atherosclerosis and cardiovascular regeneration. Open Cardiovasc Med J 2010, 4:97-104.
169. Raines E.W., Bornfeldt K.E. Integrin α7β1 COMPels smooth muscle cells to maintain their quiescence. Circ Res 2010, 106(3):427-429.
170. Hilenski L., Griendling K., Alexander R. Angiotensin AT1 receptors. Molecular mechanisms in hypertension 2006, 25-40. Taylor and Francis, London. R. Re, D. DiPette, E. Schiffrin, J. Sowers (Eds.).